Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting

Dow Jones2025-04-02

By Katherine Hamilton

Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq.

The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year.

The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday.

Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said.

The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 01, 2025 15:15 ET (19:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524125920?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 03:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524125920","market":"sg","top_or_hot":-1,"title":"Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. \n</p>\n<p>\n  The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year. \n</p>\n<p>\n  The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday. \n</p>\n<p>\n  Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said. \n</p>\n<p>\n  The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2025 15:15 ET (19:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-02 03:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. \n</p>\n<p>\n  The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year. \n</p>\n<p>\n  The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday. \n</p>\n<p>\n  Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said. \n</p>\n<p>\n  The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2025 15:15 ET (19:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524125920","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524125920","pubTimestamp":1743534900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq.The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year.The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday.Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said.The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","APTOF":"Aptose Biosciences. Inc.","USAW.SI":"AMZN 3xLongSG261006",".IXIC":"NASDAQ Composite","QLD":"2倍做多纳斯达克100指数ETF-ProShares","NVIW.SI":"NVDA 3xLongSG261006","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SQQQ":"纳指三倍做空ETF","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PSQ":"做空纳斯达克100指数ETF-ProShares","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","TSYW.SI":"TESLA 3xLongSG261006","QID":"两倍做空纳斯达克指数ETF-ProShares","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","USJW.SI":"ALPHAB 3xLongSG261006","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","TQQQ":"纳指三倍做多ETF","BK4585":"ETF&股票定投概念"},"translate_title":"Aptose Biosciences股价在纳斯达克退市前暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":1,"USAW.SI":0.6,"NQmain":1,"TSYW.SI":0.6,"QID":0.6,"SQQQ":0.6,"APTOF":1,"APTO":1,"USJW.SI":0.6,"NVIW.SI":0.6,"PSQ":0.6,"QLD":0.6,".IXIC":1,"MNQmain":0.6,"TQQQ":0.6},"content_text":"By Katherine Hamilton \n\n\n  Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. \n\n\n  The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year. \n\n\n  The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday. \n\n\n  Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said. \n\n\n  The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 15:15 ET (19:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524125920","isCrawlerRequest":true}